Skip to main content

Table 1 Clinical characteristics and survival rates of dialysis patients during 2011–2015, n = 5249

From: Effect of anti-diabetic drugs in dialysis patients with diabetes: a nationwide retrospective cohort study

Variable PDD NPDD P-value
PDD-M PDD-NM IDD NDD
n = 2601 (49.6%) n = 355 (6.8%) n = 335 (6.4%) n = 1958 (37.3%)
Age, years (mean ± SD) 61 ± 12 64 ± 13 63 ± 14 61 ± 16 0.002
Gender      0.561
 Male 1447 (56%) 200 (56%) 179 (53%) 1054 (54%)  
 Female 1154 (44%) 155 (44%) 156 (47%) 904 (46%)  
Region      0.058
 Northern 1139 (44%) 146 (41%) 165 (49%) 850 (43%)  
 Central 617 (24%) 71 (20%) 77 (23%) 477 (24%)  
 Southern/Eastern 845 (33%) 138 (39%) 93 (28%) 631 (32%)  
Insured premium (NT$)      0.505
 < 15,840 635 (24%) 96 (27%) 96 (29%) 475 (24%)  
 15,840–25,000 1187 (46%) 150 (42%) 145 (43%) 874 (45%)  
 > 25,000 779 (30%) 109 (31%) 94 (28%) 609 (31%)  
Urbanization      0.775
 Urban 1460 (56%) 199 (56%) 179 (53%) 1116 (57%)  
 Sub-urban 835 (32%) 108 (30%) 117 (35%) 622 (32%)  
 Rural 306 (12%) 48 (14%) 39 (12%) 220 (11%)  
Hospital characteristics (teaching level)       < 0.001
 Medical center 726 (28%) 91 (26%) 93 (28%) 668 (34%)  
 Region 886 (34%) 119 (33%) 113 (34%) 614 (31%)  
 Others 989 (38%) 145 (41%) 129 (38%) 676 (35%)  
Number of admissions during the 12 months leading up to dialysis       < 0.001
 0–1 1744 (67%) 212 (60%) 274 (82%) 1574 (80%)  
 > 1 857 (33%) 143 (40%) 61 (18%) 384 (20%)  
Dialysis modality       < 0.001
 Hemodialysis 2485 (95%) 340 (96%) 316 (94%) 1708 (87%)  
 Peritoneal dialysis 116 (5%) 15 (4%) 19 (6%) 250 (13%)  
Comorbidity
 Hypertension 1785 (69%) 270 (76%) 146 (43%) 987 (50%)  < 0.001
 Hyperlipidemia 790 (30%) 79 (22%) 58 (17%) 325 (17%)  < 0.001
 Gout 233 (9%) 50 (14%) 46 (14%) 338 (17%)  < 0.001
 Congestive heart failure 908 (35%) 133 (38%) 83 (25%) 501 (26%)  < 0.001
 Cerebrovascular accident 471 (18%) 57 (16%) 41 (12%) 208 (11%)  < 0.001
 COPD 185 (7%) 36 (10%) 34 (10%) 166 (9%) 0.053
 Chronic liver disease 149 (6%) 33 (9%) 19 (6%) 70 (4%)  < 0.001
 Malignancy 199 (8%) 45 (13%) 32 (10%) 212 (11%)  < 0.001
ACEI/ARB use 1555 (60%) 97 (27%) 195 (58%) 878 (45%)  < 0.001
Lipid-lowering drug use 1025 (39%) 45 (13%) 115 (34%) 431 (22%)  < 0.001
Mortality 814 (31%) 166 (47%) 121 (36%) 495 (25%)  < 0.001
Survival, years (mean ± SD) 4.1 ± 1.5 3.0 ± 2.1 4.0 ± 1.5 4.2 ± 1.6  < 0.001
  1. PDD pre-existing diabetes dialysis, NPDD non-pre-existing diabetes dialysis, PDD-M pre-existing diabetes dialysis patients continuing medication, PDD-NM pre-existing diabetes dialysis patients not continuing medication, IDD incident diabetes after dialysis, NDD non-diabetic dialysis, COPD chronic obstructive pulmonary disease, ACEI angiotensin converting enzyme inhibitors, ARB  angiotensin II receptor blockers